The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
Gwang Sil Kim (Kim GS), Joong Hyun Park (Park JH), Jong Chul Won (Won JC)
Endocrinol Metab. 2019;34(2):106-116.   Published online 2019 May 9     DOI: https://doi.org/10.3803/EnM.2019.34.2.106
Citations to this article as recorded by Crossref logo
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang
Cardiovascular Diabetology.2020;[Epub]     CrossRef
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
Kohei Kaku, Koichi Kisanuki, Mari Shibata, Takashi Oohira
Drug Safety.2019; 42(11): 1311.     CrossRef